Obinutuzumab is a monoclonal antibody used in the treatment of chronic lymphocytic leukemia and follicular lymphoma. It works by targeting CD20 on B-cells, leading to their destruction. Obinutuzumab is effective in managing hematological malignancies and improving patient outcomes. In summary, it is a critical therapy for specific blood cancers.
Obinutuzumab binds to CD20 on B-cells, inducing apoptosis and mediating antibody-dependent cellular cytotoxicity.
No published brands for this salt yet.